Trial Profile
A 26 Week Randomised, Controlled, Open Label, Multicentre, Multinational, Three-arm, Treat to Target Trial Comparing Efficacy and Safety of Three Different Dosing Regimens of Either Soluble Insulin Basal Analogue (SIBA) or Insulin Glargine With or Without Combination With OAD Treatment, in Subjects With Type 2 Diabetes Mellitus (BEGIN : FLEX)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-FLEX
- Sponsors Novo Nordisk
- 01 Dec 2015 Results of pooled analysis of 5 phase III trials (NCT01392573, NCT01617434,NCT00972283, NCT01006291 and NCT01045447) published in the Diabetes Therapy
- 08 Dec 2011 Noninferiority results presented at the 21st World Diabetes Congress.
- 16 Sep 2011 Results from the two insulin degludec arms presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.